Implications of Interleukin-6 (IL-6)-blockade for severe COVID-19 infection in patients with Multiple Myeloma

Acta Biomed. 2021 May 12;92(2):e2021205. doi: 10.23750/abm.v92i2.11395.

Authors

Nicola Sgherza¹, Paola Curci², Vanda Strafella², Rita Rizzi², Pellegrino Musto²

Affiliations

¹ a:1:{s:5:"en_US";s:147:"Hematology and Bone Marrow Transplantation Unit - AOUC Policlinico, Department of Emergency and Organ Transplantation, "Aldo Moro" University, Bari";}. nicolasgherza@libero.it.
² Hematology and Bone Marrow Transplantation Unit - AOUC Policlinico, Department of Emergency and Organ Transplantation, "Aldo Moro" University, 70124, Bari, Italy. nicolasgherza@libero.it.

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Monoclonal, Humanized
COVID-19*
Humans
Interleukin-6
Multiple Myeloma* / complications
Multiple Myeloma* / drug therapy
SARS-CoV-2

Substances

Antibodies, Monoclonal, Humanized
Interleukin-6